<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-28872" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Seminoma</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lamichhane</surname>
            <given-names>Anish</given-names>
          </name>
          <aff>Lincoln medical and mental health center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mukkamalla</surname>
            <given-names>Shiva Kumar R.</given-names>
          </name>
          <aff>Presbyterian Healthcare Services</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Anish Lamichhane declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Shiva Kumar Mukkamalla declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-28872.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Seminoma is a malignant germ cell tumor that involves most commonly the testicle or less frequently the mediastinum, the retroperitoneum, or other extra-gonadal sites. They are common among men ages 15-34 years old. It is one of the treatable and curable cancers, with a survival rate above 95% if discovered in early stages. This activity reviews the evaluation and treatment of seminoma and highlights the role of the interprofessional team in evaluating and treating patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the etiology of seminoma.</p></list-item><list-item><p>Identify the process for performing an evaluation of seminoma.</p></list-item><list-item><p>Outline the management of seminoma.</p></list-item><list-item><p>Summarize the importance of collaboration and coordination among an interprofessional team to improve outcomes of patients with seminoma.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28872&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28872">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-28872.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Testicular neoplasm is one of the most common causes of testicular mass. It occurs in approximately 5 per 100,000 men, mainly in the age group of 15-34 years. Seminoma is a malignant germ cell tumor that involves most commonly the testicle or less frequently the mediastinum, the retroperitoneum, or other&#x000a0;extra-gonadal sites. It is one of the treatable and curable cancers, with a survival rate of over 95% if discovered in early stages.<xref ref-type="bibr" rid="article-28872.r1">[1]</xref><xref ref-type="bibr" rid="article-28872.r2">[2]</xref><xref ref-type="bibr" rid="article-28872.r3">[3]</xref><xref ref-type="bibr" rid="article-28872.r4">[4]</xref></p>
        <p>Testicular germ cell tumors (GCTs) have different pathological subtypes, including seminoma, teratoma, choriocarcinoma, embryonal, and yolk sac carcinoma. The most significant clinical distinction is between seminoma and nonseminoma, two broad categories with different treatment algorithms. Seminoma based on classification is pure seminoma upon histopathological review. The presence of any nonseminatous elements (even if seminoma is prevalent) changes the classification to nonseminoma.</p>
      </sec>
      <sec id="article-28872.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The exact etiology of seminoma remains undetermined. However, the following factors are associated with an increase in the risk of seminoma:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>History of Cryptorchidism</bold>: Risk of seminoma increases with the history of cryptorchidism. There is 10&#x000a0;to 40 times higher risk in patients with an undescended testis, 10% of the patients with cryptorchidism develop germ cell tumor.<xref ref-type="bibr" rid="article-28872.r5">[5]</xref>&#x000a0;An abdominal testis usually develops seminoma while a testis surgically brought to the scrotum by orchiopexy is a non-seminomatous germ cell tumor.</p>
          </list-item>
          <list-item>
            <p><bold>Environmental Exposure</bold>: Exposure to chemical compounds like organochlorines, polychlorinated biphenyls, polyvinyl chlorides, phthalates, marijuana, and tobacco is associated with an increased risk of seminoma or other germ cell tumors.<xref ref-type="bibr" rid="article-28872.r6">[6]</xref><xref ref-type="bibr" rid="article-28872.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Infections</bold>: History of mumps viral infection is related to increased risk of germ cell tumors.<xref ref-type="bibr" rid="article-28872.r8">[8]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Others</bold>: Other factors include trauma, maternal estrogen exposure, family history of testicular tumors, intersex syndromes (insensitive androgen syndrome and gonadal dysgenesis), and history of cancer in the contralateral testicle.<xref ref-type="bibr" rid="article-28872.r9">[9]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Genetics: </bold>Genetic changes in the form of amplification and deletions are seen in 12p11.2-p12.1 chromosomal regions. Coffey and colleagues demonstrated that only seminomas contain activating mutations of the KIT gene.<xref ref-type="bibr" rid="article-28872.r10">[10]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28872.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Testicular germ cell tumors (GCTs) account for the most common malignancy in men aged 15&#x000a0;to 34 years. However, it accounts for less than 1% of all male tumors. The incidence of testicular tumors is rising from the past 20 years. In the United States, testicular seminoma is the most common subtype of testicular cancer.<xref ref-type="bibr" rid="article-28872.r11">[11]</xref> A higher incidence of seminoma is seen among Whites than in African Americans, and the rate has increased in the White population over recent decades.<xref ref-type="bibr" rid="article-28872.r12">[12]</xref></p>
      </sec>
      <sec id="article-28872.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Testicular seminoma is a germ cell neoplasm originating from the seminiferous tubules, due to malignant transformation of primordial germ cells. The exact molecular derangements underlying this transformation are not clearly understood, but the most common genetic finding is the gain of genetic material from chromosome 12p. Some of the mutations noticed in germ cell tumors include BRAF, KIT, KRAS, NRAS, and TP53, although single-gene mutations are relatively uncommon.<xref ref-type="bibr" rid="article-28872.r13">[13]</xref></p>
        <p>Seminomas can be subdivided into one of three categories based on histology: classic, anaplastic, and spermatocytic. In testicular seminoma, alpha-fetoprotein (AFP) is in the normal range. If AFP is elevated and the presence of noseminomatous elements in histopathological specimens makes the diagnosis of nonseminotaous germ cell tumor. Germ cell carcinoma in situ (CIS) is a premalignant condition with the propensity of progression to seminoma or embryonal cancer. Patients with cryptorchidism, infertility, prior contralateral germ cell tumors, intersex disorders, or atrophic testes more commonly have CIS. Testicular microcalcifications observed on scrotal ultrasound were implicated in the testicular carcinoma development.</p>
      </sec>
      <sec id="article-28872.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>
<bold>Histological Findings</bold>
</p>
        <p>Most commonly, there is a diffuse arrangement of pale cells that is interrupted by fibrovascular septa containing lymphocytes. The tumor cells characteristically&#x000a0;have pale to clear cytoplasm, with crisp cytoplasmic membranes and polygonal nuclei with finely granular chromatin and frequently flattened edges. One or more large, centrally located nucleoli are present. The abundant cytoplasm results in relatively evenly spaced, non-overlapping nuclei in most cases.&#x000a0;The cytoplasmic clarity is attributable to abundant glycogen particles demonstrable with the periodic acid-Schiff stain. Less commonly, the cytoplasm is denser, and the nuclei more crowded. This may result in a plasmacytoid appearance.&#x000a0;A variably prominent lymphocytic infiltrate occurs in almost every case and a granulomatous reaction in more than half. Approximately 10-20% of tumors contain admixed syncytiotrophoblast cells that vary in prominence from widely scattered to prominent aggregates.<xref ref-type="bibr" rid="article-28872.r14">[14]</xref></p>
        <p>
<bold>Immunohistochemical Findings</bold>
</p>
        <p>Seminomas stain for antigens characteristic of immature, fetal-type germ cells (gonocytes), including placental alkaline phosphatase (86-95%; cytoplasmic membrane), KIT (90-100%; cytoplasmic membrane), OCT3/4 (100%; nuclear), SALL4 (100%; nuclear), and SOX17 (95%; nuclear). Podoplanin is also positive (100%; cytoplasmic membrane). Cytokeratin AE1/AE3 immunoreactivity varies (20-36%), but is often negative or stains the cytoplasm of only a minority of tumor cells,&#x000a0;often in a para nuclear dot-like pattern. CD30 is characteristically negative, as is epithelial membrane antigen (2%). Stains for alpha-fetoprotein are always negative.</p>
      </sec>
      <sec id="article-28872.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Seminoma usually presents as a nodule or painless swelling of the testis. It may be an incidental finding by the patients or his partner. Patients sometimes complain of a dull ache or heavy sensation in the lower abdomen, perineal area, or scrotum. Rarely, acute pain or hematospermia may be the presenting symptoms. Cases of advanced disease, with metastases, present as a neck mass (cervical or supraclavicular lymph node metastases), cough or dyspnea (pulmonary metastases), anorexia, nausea, vomiting, or gastrointestinal hemorrhage (gastroduodenal metastases), bone pain (skeletal metastases), central or peripheral nerve involvement (cerebral, spinal cord, or peripheral nerve involvement). History of cryptorchidism and orchiopexy is noted in some cases.</p>
      </sec>
      <sec id="article-28872.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>In patients with a suspected testicular mass, initial workup includes laboratory tests and imaging results. Serum tumor marker levels, including alpha-fetoprotein (AFP), beta-human chorionic gonadotropin (beta-HCG), and lactate dehydrogenase (LDH), are measured. Serum beta-HCG and LDH levels can be elevated in seminomas while AFP is not raised in pure seminomas. LDH is a less specific marker, but levels can correlate with overall tumor burden. Beta-HCG levels are increased in 5-10% of patients with seminoma, and levels may correlate with metastatic disease but not with overall survival. Placenta-like alkaline phosphatase may be elevated in patients with seminoma, especially when the tumor burden increases; however, these may also be increased with smoking.</p>
        <p>Scrotal ultrasonography is done to rule out other conditions. It shows&#x000a0;a homogeneous hypoechoic intratesticular mass, more extensive lesions may be inhomogeneous. Cystic areas and calcifications are less common in seminomas than in non-seminomatous tumors. For a definitive diagnosis, an orchiectomy is performed, which is diagnostic as well as therapeutic. Histologic and laboratory results confirm the diagnosis and help differentiate the type of testicular cancers.</p>
        <p>Once the diagnosis is confirmed, a chest x-ray or chest CT scan, abdominal and pelvic CT scan, MRI brain, and bone scan may be done to look for metastases depending upon the stage and signs and symptoms of metastases. PET can be used to assess disease activity following chemotherapy treatment and to identify recurrences.<xref ref-type="bibr" rid="article-28872.r15">[15]</xref></p>
        <p>The most commonly used staging systems for germ cell tumors are those proposed by the Americal Joint Commission on Cancer (AJCC) and the International Union Against Cancer (IUAC).</p>
        <p>Risk stratification of seminomas is not dependent on serum tumor markers (unlike non-seminomatous germ cell tumors) but rather based on the presence or absence of nonpulmonary visceral metastases.<xref ref-type="bibr" rid="article-28872.r16">[16]</xref></p>
      </sec>
      <sec id="article-28872.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Radical orchiectomy provides both diagnostic and therapeutic implications in seminoma. It is indicated for all stages of the disease. Adjuvant chemotherapy or radiotherapy depends upon the clinical staging that follows radical inguinal orchiectomy. Generally, treatment plans are as follows:<xref ref-type="bibr" rid="article-28872.r17">[17]</xref><xref ref-type="bibr" rid="article-28872.r18">[18]</xref><xref ref-type="bibr" rid="article-28872.r19">[19]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Stage I:</bold> For patients with stage I seminoma, orchiectomy is usually curative.<xref ref-type="bibr" rid="article-28872.r20">[20]</xref><xref ref-type="bibr" rid="article-28872.r21">[21]</xref>&#x000a0;Options for post-orchiectomy management include surveillance alone or adjuvant chemotherapy with one single infusion of carboplatin or prophylactic radiotherapy (declining interest).</p>
          </list-item>
          <list-item>
            <p><bold>Stage II:&#x000a0;</bold>Following radical inguinal orchiectomy, the treatment of stage II diseases depends on the extent of the lymph node involvement. Radiotherapy with or without cisplatin-based chemotherapy is recommended.</p>
          </list-item>
          <list-item>
            <p><bold>Stage III:&#x000a0;</bold>For stage III diseases,&#x000a0;chemotherapy with bleomycin, etoposide, and cisplatin (BEP) or etoposide and cisplatin (EP) is preferred. Radiotherapy may be indicated in select cases.<xref ref-type="bibr" rid="article-28872.r22">[22]</xref>&#x000a0;In patients with an intermediate prognosis, it might be hard to tolerate bleomycin, and therefore the addition of ifosfamide to etoposide and cisplatin (VIP) is reasonable.<xref ref-type="bibr" rid="article-28872.r23">[23]</xref></p>
          </list-item>
        </list>
        <p>After treatment patient requires life long follow up. Surveillance includes the following, with the frequency determined by the disease stage and duration of follow up.</p>
        <list list-type="bullet">
          <list-item>
            <p>History and physical examination</p>
          </list-item>
          <list-item>
            <p>Serum tumor markers ( beta-hCG, LDH, AFP)</p>
          </list-item>
          <list-item>
            <p>Chest radiography</p>
          </list-item>
          <list-item>
            <p>CT scan of the abdomen, with or without CT scan of the pelvis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28872.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Histological differential diagnosis of seminoma include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Non-seminomatous germ cell tumor, including embryonal carcinoma, cholangiocarcinoma, yolk sac tumor or teratoma</p>
          </list-item>
          <list-item>
            <p>Leydig and Sertoli cell tumors</p>
          </list-item>
          <list-item>
            <p>Granulosa cell tumors</p>
          </list-item>
          <list-item>
            <p>Gonadoblastoma</p>
          </list-item>
          <list-item>
            <p>Lymphoma</p>
          </list-item>
          <list-item>
            <p>Mesothelioma</p>
          </list-item>
          <list-item>
            <p>Adenocarcinoma of the rete testis</p>
          </list-item>
          <list-item>
            <p>Epidermoid cyst</p>
          </list-item>
          <list-item>
            <p>Metastatic carcinoma</p>
          </list-item>
          <list-item>
            <p>Epididymitis</p>
          </list-item>
          <list-item>
            <p>Hydrocele</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28872.s11" sec-type="Surgical Oncology">
        <title>Surgical Oncology</title>
        <p>Radical inguinal orchiectomy is the standard procedure for diagnostic and therapeutic purposes. Trans scrotal orchiectomy or biopsy of the testicular mass is contraindicated for the risk of tumor seeding of the lymphatic drainage. Spinal or general anesthesia may be used. An inguinal incision is made to expose the external and internal iliac canal. External iliac fascia is opened, revealing the spermatic cord. The spermatic cord is controlled to stop retroperitoneal lymphatic and venous drainage of tumor cells. After that, deliver the testis from the scrotum and ligate vas deferens and spermatic arteries separately. Retroperitoneal lymph node dissection is done if necessary. Reapproximate the external oblique fascia and close the skin in standard fashion. Conduct a follow-up study by staging and referring the patient for appropriate adjuvant therapies.</p>
      </sec>
      <sec id="article-28872.s12" sec-type="Staging">
        <title>Staging</title>
        <p>In the TNM classification system, assessments of the primary tumor (T), lymph node involvement (N), and distant metastases (M) are combined with serum tumor marker values (S) like AFP, beta-HCG, and LDH to define prognostic stage groups from I to III. The treatment plan, including chemotherapy and radiotherapy, depends upon the stage of the tumor diagnosed.</p>
        <p>
<bold>AJCC TNM staging classification 8th ed., 2017</bold>
<xref ref-type="bibr" rid="article-28872.r24">[24]</xref>
</p>
        <p>
<bold>Definitions for T, N, M:</bold>
</p>
        <p>
<italic toggle="yes">Pathological T</italic>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Tx Primary tumor cannot be assessed</p>
          </list-item>
          <list-item>
            <p>T0 No evidence of primary tumor</p>
          </list-item>
          <list-item>
            <p>Tis Germ cell neoplasia in situ</p>
          </list-item>
          <list-item>
            <p>T1 Tumor limited to the testicle (including rete testis invasion) without lymphovascular invasion</p>
          </list-item>
          <list-item>
            <p>T1a Tumor smaller than 3 cm in size</p>
          </list-item>
          <list-item>
            <p>T1b Tumor 3 cm or larger</p>
          </list-item>
          <list-item>
            <p>T2 Tumor limited to the testicle (including rete testis invasion) with lymphovascular invasion or tumor invading hilar soft tissue or epididymis or penetrating visceral mesothelial layer covering the external surface of tunica albuginea with or without lymphovascular invasion</p>
          </list-item>
          <list-item>
            <p>T3 Tumor directly invades spermatic cord soft tissue with or without lymphovascular invasion</p>
          </list-item>
          <list-item>
            <p>T4 Tumor invades scrotum with or without lymphovascular invasion</p>
          </list-item>
        </list>
        <p>
<italic toggle="yes">Clinical N</italic>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Nx Regional lymph nodes cannot be assessed</p>
          </list-item>
          <list-item>
            <p>N0 No regional lymph node metastasis</p>
          </list-item>
          <list-item>
            <p>N1 Metastasis with a lymph node mass 2 cm or smaller in greatest dimension or multiple lymph nodes, none larger than 2 cm in greatest dimension</p>
          </list-item>
          <list-item>
            <p>N2 Metastasis with a lymph node mass larger than 2 cm but not larger than 5 cm in greatest dimension or multiple lymph nodes, if any mass larger than 2 cm but not larger than 5 cm in greatest dimension</p>
          </list-item>
          <list-item>
            <p>N3 Metastasis with a lymph node mass larger than 5 cm in greatest dimension</p>
          </list-item>
        </list>
        <p>
<italic toggle="yes">Pathological N</italic>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Nx Regional lymph nodes cannot be assessed</p>
          </list-item>
          <list-item>
            <p>N0 No regional lymph node metastasis</p>
          </list-item>
          <list-item>
            <p>N1 Metastasis with a lymph node mass 2 cm or smaller in greatest dimension and less than or equal to five nodes positive, none larger than 2 cm in greatest dimension</p>
          </list-item>
          <list-item>
            <p>N2 Metastasis with a lymph node mass larger than 2 cm but not larger than 5 cm in greatest dimension; or more than five nodes positive, none larger than 5 cm; or evidence of extranodal extension of tumor</p>
          </list-item>
          <list-item>
            <p>N3 Metastasis with a lymph node mass larger than 5 cm in greatest dimension</p>
          </list-item>
        </list>
        <p>
<italic toggle="yes">Clinical or pathological M</italic>
</p>
        <list list-type="bullet">
          <list-item>
            <p>M0 No distant metastases</p>
          </list-item>
          <list-item>
            <p>M1 Distant metastases</p>
          </list-item>
          <list-item>
            <p>M1a Non-retroperitoneal nodal or pulmonary metastases</p>
          </list-item>
          <list-item>
            <p>M1b Non-pulmonary visceral metastases</p>
          </list-item>
        </list>
        <p>
<italic toggle="yes">Serum markers S</italic>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Sx Marker studies not available or not performed</p>
          </list-item>
          <list-item>
            <p>S0 Marker study levels within normal limits</p>
          </list-item>
          <list-item>
            <p>S1 LDH &#x0003c;1.5 x N* and hCG (mIU/mL) &#x0003c;5,000 and AFP (ng/mL) &#x0003c;1,000</p>
          </list-item>
          <list-item>
            <p>S2 LDH 1.5&#x02013;10 x N* or hCG (mIU/mL) 5,000&#x02013;50,000 or AFP (ng/mL) 1,000&#x000a0;to 10,000</p>
          </list-item>
          <list-item>
            <p>S3 LDH &#x0003e;10 x N* or hCG (mIU/mL) &#x0003e;50,000 or AFP (ng/mL) &#x0003e;10,000</p>
          </list-item>
        </list>
        <p>
<bold>AJCC prognostic stage groups</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Stage 0</bold> pTis N0 M0 S0</p>
          </list-item>
          <list-item>
            <p><bold>Stage I</bold> pT1-T4 N0 M0 Sx</p>
          </list-item>
          <list-item>
            <p><bold>Stage IA</bold> pT1 N0 M0 S0</p>
          </list-item>
          <list-item>
            <p><bold>Stage IB</bold> pT2 N0 M0 S0&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;pT3 N0 M0 S0&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;pT4 N0 M0 S0</p>
          </list-item>
          <list-item>
            <p><bold>Stage IS</bold> Any pT/Tx N0 M0 S1-3</p>
          </list-item>
          <list-item>
            <p><bold>Stage II</bold> Any pT/Tx N1-3 M0 Sx</p>
          </list-item>
          <list-item>
            <p><bold>Stage IIA</bold> Any pT/Tx N1 M0 S0&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; Any pT/Tx N1 M0 S1</p>
          </list-item>
          <list-item>
            <p><bold>Stage IIB</bold> Any pT/Tx N2 M0 S0&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; Any pT/Tx N2 M0 S1</p>
          </list-item>
          <list-item>
            <p><bold>Stage IIC</bold> Any pT/Tx N3 M0 S0&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; Any pT/Tx N3 M0 S1</p>
          </list-item>
          <list-item>
            <p><bold>Stage III</bold> Any pT/Tx Any N M1 SX</p>
          </list-item>
          <list-item>
            <p><bold>Stage IIIA</bold> Any pT/Tx Any N M1a S0&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; Any pT/Tx Any N M1a S1</p>
          </list-item>
          <list-item>
            <p><bold>Stage IIIB</bold> Any pT/Tx N1-3 M0 S2&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; Any pT/Tx Any N M1a S2</p>
          </list-item>
          <list-item>
            <p><bold>Stage IIIC</bold> Any pT/Tx N1-3 M0 S3&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; Any pT/Tx Any N M1a S3&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; Any pT/Tx Any N M1b Any S</p>
          </list-item>
        </list>
        <p>*Serum tumor marker values (S) are measured after orchiectomy.</p>
      </sec>
      <sec id="article-28872.s13" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>According to information from the Surveillance, Epidemiology, and Rend-Results (SEER) database, as published on the American Cancer Society webpage, the 5-year relative survival rates for testicular cancer are;</p>
        <list list-type="bullet">
          <list-item>
            <p>Localized disease (stage I) 99%</p>
          </list-item>
          <list-item>
            <p>Regional disease (stage II) 96%</p>
          </list-item>
          <list-item>
            <p>Distant disease (Stage III) 73%</p>
          </list-item>
        </list>
        <p>Patients with testicular cancer are at an increased risk of secondary cancers because of their young age at diagnosis, high cure rate, and exposure to radiation, chemotherapy, or both. Tumors included malignant mesothelioma and those of the lung, colon, bladder, pancreas, and stomach.</p>
      </sec>
      <sec id="article-28872.s14" sec-type="Complications">
        <title>Complications</title>
        <p>Both radiation therapy and chemotherapy have long-term complications in survivors of testicular cancer. With post-therapy life estimates being approximately more than 40 years in these young individuals, the morbidity of long term complications can be very significant.</p>
        <list list-type="bullet">
          <list-item>
            <p>Chemotherapy related neurotoxicity: Peripheral neuropathy is a common adverse event of platinum chemotherapy. About 20 to 40% of patients will develop neurotoxicity, which can be painful and also cause permanent sensory abnormalities.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Cardiovascular complications: There can be up to a seven-fold increased risk of developing a cardiac event in survivors of testicular cancer who received cisplatin-based chemotherapy.<xref ref-type="bibr" rid="article-28872.r25">[25]</xref></p>
          </list-item>
          <list-item>
            <p>Infertility and hypogonadism: Chemotherapy and the use of radiation to seminoma affected scrotum can result in oligospermia and infertility. Thus, sperm banking must be offered to all patients before undergoing chemotherapy or radiotherapy. The risk of infertility is directly proportional to the intensity and duration of the treatment. Hypogonadism or testicular dysfunction is a common sequela among survivors of testicular cancer.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Ototoxicity: Cisplatin can cause permanent, sensorineural hearing loss and tinnitus.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Secondary neoplasms: Both chemotherapy and radiotherapy can increase the risk of secondary malignant tumors in survivors. Etoposide can cause treatment-related leukemia, and risk is proportional to the total dose administered.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28872.s15" sec-type="Postoperative and Rehabilitation Care">
        <title>Postoperative and Rehabilitation Care</title>
        <p>Following radical inguinal orchiectomy, postoperative reconstructive surgery with prosthetic testicle is gaining popularity. The operation is comparable to an inguinal herniorrhaphy, and the patient should do limited physical activity for a brief post-surgery period. A short course of pain management medication is advised. Complications are rare but can include wound infection, hematoma, anesthetic risk, and inguinal skin numbness.</p>
        <p>Surveillance for seminomas after initial management is as follows:</p>
        <p>Clinical stage I seminoma after orchiectomy alone:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Year 1</bold>:&#x000a0;History and physical examination (H&#x00026;P) every 3-6 months, CT scan of abdomen +/- pelvis at 3, 6, and 12 months.</p>
          </list-item>
          <list-item>
            <p><bold>Years 2 and 3</bold>:&#x000a0;H&#x00026;P and CT scan of abdomen +/- pelvis every 6-12 months.</p>
          </list-item>
          <list-item>
            <p><bold>Years 4 and 5</bold>: H&#x00026;P annually, and CT scan of abdomen +/- pelvis every 12-24 months.</p>
          </list-item>
        </list>
        <p>&#x000a0; *At any point in five years, a chest x-ray is recommended as clinically indicated, and chest CT with contrast is obtained if the patient is symptomatic. Serum tumor markers are optional with&#x000a0;H&#x00026;P.</p>
        <p>Clinical stage I seminoma after adjuvant therapy (chemotherapy or radiation):</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Years 1 and 2</bold>:&#x000a0;H&#x00026;P every 6-12 months, and CT scan of abdomen +/- pelvis annually</p>
          </list-item>
          <list-item>
            <p><bold>Year 3</bold>: H&#x00026;P and CT of abdomen +/- pelvis annually</p>
          </list-item>
          <list-item>
            <p><bold>Years 4 and 5</bold>: H&#x00026;P annually</p>
          </list-item>
        </list>
        <p>*At any point in five years, a chest x-ray is recommended as clinically indicated, and chest CT with contrast is obtained&#x000a0;if the patient is symptomatic. Serum tumor markers are optional with&#x000a0;H&#x00026;P.</p>
        <p>Clinical stage IIA and non-bulky IIB seminoma after radiation or chemotherapy:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Year 1</bold>: H&#x00026;P every three months, CT scan of abdomen +/- pelvis at three months and then every 6-12 months, and chest x-ray every six months.</p>
          </list-item>
          <list-item>
            <p><bold>Year 2</bold>: H&#x00026;P every six months, CT scan of abdomen +/- pelvis annually, and chest x-ray every six months.</p>
          </list-item>
          <list-item>
            <p><bold>Year 3</bold>: H&#x00026;P every six months,&#x000a0;and CT scan of abdomen +/- pelvis annually.</p>
          </list-item>
          <list-item>
            <p><bold>Year 4 and 5</bold>: H&#x00026;P every six months and CT scan fo abdomen +/- pelvis as clinically indicated.</p>
          </list-item>
        </list>
        <p>*Serum tumor markers are optional with&#x000a0;H&#x00026;P.</p>
        <p>Clinical bulky stage IIB, IIC, and stage III seminoma after chemotherapy:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Year 1</bold>: H&#x00026;P with serum tumor markers every two months, CT scan of abdomen/pelvis every four months, and chest X-ray every two months.</p>
          </list-item>
          <list-item>
            <p><bold>Year 2</bold>: H&#x00026;P with serum tumor markers every three months, CT scan of abdomen/pelvis every six months, and chest X-ray every three months.</p>
          </list-item>
          <list-item>
            <p><bold>Years 3 and 4</bold>: H&#x00026;P with serum tumor markers every six months, CT scan of abdomen/pelvis chest X-ray annually.</p>
          </list-item>
          <list-item>
            <p><bold>Year 5</bold>:&#x000a0;H&#x00026;P with serum tumor markers annually, CT scan of abdomen/pelvis&#x000a0;as clinically indicated, and chest X-ray annually.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28872.s16" sec-type="Consultations">
        <title>Consultations</title>
        <p>Diagnosis and management of seminoma need a multidisciplinary approach and teamwork. Following specialties should work in coordination for better management</p>
        <list list-type="bullet">
          <list-item>
            <p>Urology</p>
          </list-item>
          <list-item>
            <p>Surgical oncology</p>
          </list-item>
          <list-item>
            <p>Radiation oncology</p>
          </list-item>
          <list-item>
            <p>Medical oncology</p>
          </list-item>
          <list-item>
            <p>Radiology</p>
          </list-item>
          <list-item>
            <p>Histopathology</p>
          </list-item>
          <list-item>
            <p>Cosmetic surgery</p>
          </list-item>
          <list-item>
            <p>Fertility medicine</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28872.s17" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>There is no useful screening test for the detection of testicular cancer. Hence, the young population needs to be aware of the importance of&#x000a0;self-examination. Early detection of the disease has an excellent prognosis. Therefore, self-examination should be encouraged in the patient with a positive family history of testicular cancer or a history of cryptorchidism.</p>
        <p>Sperm banking should be discussed in all patients of reproductive age. The discussion should take place before the patient undergoes any procedure that may compromise fertility, including orchiectomy, chemotherapy, or radiotherapy. If the patient desires sperm banking, it may be performed before or after surgery, but must be completed before radiation therapy or chemotherapy.</p>
      </sec>
      <sec id="article-28872.s18" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Timely diagnosis and management of testicular cancers result in excellent prognosis and near-normal life expectancy. Therefore, it is of utmost importance for ER providers and primary care providers to have a low threshold for&#x000a0;evaluating testicular symptoms in young patients, with a complete history and physical examination and urgent testicular ultrasound. Based on the results of the ultrasound and level of clinical suspicion, an urgent referral or consultation with a urologist is needed. Once orchiectomy is performed, the patient must be followed by a multi-disciplinary oncology team involving medical oncologists, radiation oncologists, and surgical oncologists to discuss staging, adjuvant therapies, and surveillance.</p>
      </sec>
      <sec id="article-28872.s19">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28872&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28872">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/cancer/seminoma/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=28872">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/28872/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=28872">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-28872.s20">
        <fig id="article-28872.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Ultrasound of Seminoma of the Testicle Contributed by Dawn Light, MD, MPH</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Semanoma" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-28872.s21">
        <title>References</title>
        <ref id="article-28872.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bokemeyer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nichols</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Droz</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Schmoll</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Horwich</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gerl</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fossa</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Beyer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pont</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kanz</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Einhorn</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hartmann</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis.</article-title>
            <source>J Clin Oncol</source>
            <year>2002</year>
            <month>Apr</month>
            <day>01</day>
            <volume>20</volume>
            <issue>7</issue>
            <fpage>1864</fpage>
            <page-range>1864-73</page-range>
            <pub-id pub-id-type="pmid">11919246</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28872.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dieckmann</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Richter-Simonsen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kulejewski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ikogho</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zecha</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Anheuser</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pichlmeier</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Isbarn</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Testicular Germ-Cell Tumours: A Descriptive Analysis of Clinical Characteristics at First Presentation.</article-title>
            <source>Urol Int</source>
            <year>2018</year>
            <volume>100</volume>
            <issue>4</issue>
            <fpage>409</fpage>
            <page-range>409-419</page-range>
            <pub-id pub-id-type="pmid">29649815</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28872.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chung</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Warde</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Testicular cancer: seminoma.</article-title>
            <source>BMJ Clin Evid</source>
            <year>2011</year>
            <month>Jan</month>
            <day>25</day>
            <volume>2011</volume>
            <pub-id pub-id-type="pmid">21477387</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28872.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fung</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dinh</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Fossa</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Travis</surname>
                <given-names>LB</given-names>
              </name>
            </person-group>
            <article-title>Testicular Cancer Survivorship.</article-title>
            <source>J Natl Compr Canc Netw</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>17</volume>
            <issue>12</issue>
            <fpage>1557</fpage>
            <page-range>1557-1568</page-range>
            <pub-id pub-id-type="pmid">31805527</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28872.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Batool</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Karimi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>XN</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>YX</given-names>
              </name>
            </person-group>
            <article-title>Testicular germ cell tumor: a comprehensive review.</article-title>
            <source>Cell Mol Life Sci</source>
            <year>2019</year>
            <month>May</month>
            <volume>76</volume>
            <issue>9</issue>
            <fpage>1713</fpage>
            <page-range>1713-1727</page-range>
            <pub-id pub-id-type="pmid">30671589</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28872.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barchi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Innocenzi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Giannattasio</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Dolci</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Grimaldi</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Cannabinoid Receptors Signaling in the Development, Epigenetics, and Tumours of Male Germ Cells.</article-title>
            <source>Int J Mol Sci</source>
            <year>2019</year>
            <month>Dec</month>
            <day>18</day>
            <volume>21</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">31861494</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28872.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gurney</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shaw</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Stanley</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Signal</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Sarfati</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Cannabis exposure and risk of testicular cancer: a systematic review and meta-analysis.</article-title>
            <source>BMC Cancer</source>
            <year>2015</year>
            <month>Nov</month>
            <day>11</day>
            <volume>15</volume>
            <fpage>897</fpage>
            <pub-id pub-id-type="pmid">26560314</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28872.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garolla</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vitagliano</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Muscianisi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Valente</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Ghezzi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Andrisani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ambrosini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Foresta</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Role of Viral Infections in Testicular Cancer Etiology: Evidence From a Systematic Review and Meta-Analysis.</article-title>
            <source>Front Endocrinol (Lausanne)</source>
            <year>2019</year>
            <volume>10</volume>
            <fpage>355</fpage>
            <pub-id pub-id-type="pmid">31263452</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28872.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fukawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kanayama</surname>
                <given-names>HO</given-names>
              </name>
            </person-group>
            <article-title>Current knowledge of risk factors for testicular germ cell tumors.</article-title>
            <source>Int J Urol</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>25</volume>
            <issue>4</issue>
            <fpage>337</fpage>
            <page-range>337-344</page-range>
            <pub-id pub-id-type="pmid">29345008</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28872.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coffey</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Linger</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pugh</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dudakia</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sokal</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Easton</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Timothy Bishop</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Stratton</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Huddart</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rapley</surname>
                <given-names>EA</given-names>
              </name>
            </person-group>
            <article-title>Somatic KIT mutations occur predominantly in seminoma germ cell tumors and are not predictive of bilateral disease: report of 220 tumors and review of literature.</article-title>
            <source>Genes Chromosomes Cancer</source>
            <year>2008</year>
            <month>Jan</month>
            <volume>47</volume>
            <issue>1</issue>
            <fpage>34</fpage>
            <page-range>34-42</page-range>
            <pub-id pub-id-type="pmid">17943970</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28872.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ghazarian</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Trabert</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Devesa</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>McGlynn</surname>
                <given-names>KA</given-names>
              </name>
            </person-group>
            <article-title>Recent trends in the incidence of testicular germ cell tumors in the United States.</article-title>
            <source>Andrology</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>3</volume>
            <issue>1</issue>
            <fpage>13</fpage>
            <page-range>13-8</page-range>
            <pub-id pub-id-type="pmid">25331158</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28872.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nigam</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Aschebrook-Kilfoy</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Shikanov</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Eggener</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Increasing incidence of testicular cancer in the United States and Europe between 1992 and 2009.</article-title>
            <source>World J Urol</source>
            <year>2015</year>
            <month>May</month>
            <volume>33</volume>
            <issue>5</issue>
            <fpage>623</fpage>
            <page-range>623-31</page-range>
            <pub-id pub-id-type="pmid">25030752</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28872.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sheikine</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Genega</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Melamed</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Reuter</surname>
                <given-names>VE</given-names>
              </name>
              <name>
                <surname>Ye</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Molecular genetics of testicular germ cell tumors.</article-title>
            <source>Am J Cancer Res</source>
            <year>2012</year>
            <volume>2</volume>
            <issue>2</issue>
            <fpage>153</fpage>
            <page-range>153-67</page-range>
            <pub-id pub-id-type="pmid">22432056</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28872.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tourne</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Radulescu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Allory</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>[Testicular germ cell tumors: Histopathological and molecular features].</article-title>
            <source>Bull Cancer</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>106</volume>
            <issue>4</issue>
            <fpage>328</fpage>
            <page-range>328-341</page-range>
            <pub-id pub-id-type="pmid">30905378</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28872.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zores</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mouracade</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Duclos</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Saussine</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Jacqmin</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>[Surveillance of stage I testicular seminoma: 20 years oncological results].</article-title>
            <source>Prog Urol</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>25</volume>
            <issue>5</issue>
            <fpage>282</fpage>
            <page-range>282-7</page-range>
            <pub-id pub-id-type="pmid">25724863</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28872.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <article-title>International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group.</article-title>
            <source>J Clin Oncol</source>
            <year>1997</year>
            <month>Feb</month>
            <volume>15</volume>
            <issue>2</issue>
            <fpage>594</fpage>
            <page-range>594-603</page-range>
            <pub-id pub-id-type="pmid">9053482</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28872.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stokes</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Amini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Maroni</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Kessler</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Stokes</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cost</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Greffe</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Garrington</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Cost</surname>
                <given-names>NG</given-names>
              </name>
            </person-group>
            <article-title>Patterns of care and survival outcomes for adolescent and young adult patients with testicular seminoma in the United States: A National Cancer Database analysis.</article-title>
            <source>J Pediatr Urol</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>13</volume>
            <issue>4</issue>
            <fpage>386.e1</fpage>
            <page-range>386.e1-386.e7</page-range>
            <pub-id pub-id-type="pmid">28153774</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28872.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chovanec</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hanna</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Cary</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Einhorn</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Albany</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Management of stage I testicular germ cell tumours.</article-title>
            <source>Nat Rev Urol</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>13</volume>
            <issue>11</issue>
            <fpage>663</fpage>
            <page-range>663-673</page-range>
            <pub-id pub-id-type="pmid">27618772</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28872.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Motzer</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Jonasch</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Beard</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bhayani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bolger</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Choueiri</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Costello</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Derweesh</surname>
                <given-names>IH</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hancock</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Kuzel</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>ET</given-names>
              </name>
              <name>
                <surname>Lau</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Michaelson</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Olencki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Pili</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Plimack</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Rampersaud</surname>
                <given-names>EN</given-names>
              </name>
              <name>
                <surname>Redman</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Ryan</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Sheinfeld</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shuch</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sircar</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Somer</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wilder</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Dwyer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Testicular Cancer, Version 2.2015.</article-title>
            <source>J Natl Compr Canc Netw</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>13</volume>
            <issue>6</issue>
            <fpage>772</fpage>
            <page-range>772-99</page-range>
            <pub-id pub-id-type="pmid">26085393</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28872.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Faouzi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ouguellit</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Loriot</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>[Stage 1 germ-cell tumour].</article-title>
            <source>Bull Cancer</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>106</volume>
            <issue>10</issue>
            <fpage>887</fpage>
            <page-range>887-895</page-range>
            <pub-id pub-id-type="pmid">31088678</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28872.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stephenson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Eggener</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Bass</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Chelnick</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Daneshmand</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gilligan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Karam</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Leibovich</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Liauw</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Masterson</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Meeks</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Pierorazio</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sheinfeld</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and Treatment of Early Stage Testicular Cancer: AUA Guideline.</article-title>
            <source>J Urol</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>202</volume>
            <issue>2</issue>
            <fpage>272</fpage>
            <page-range>272-281</page-range>
            <pub-id pub-id-type="pmid">31059667</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28872.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alsdorf</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Seidel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bokemeyer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Oing</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Current pharmacotherapy for testicular germ cell cancer.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2019</year>
            <month>May</month>
            <volume>20</volume>
            <issue>7</issue>
            <fpage>837</fpage>
            <page-range>837-850</page-range>
            <pub-id pub-id-type="pmid">30849243</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28872.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fizazi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Delva</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Caty</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chevreau</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kerbrat</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rolland</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Priou</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Geoffrois</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rixe</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Beuzeboc</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Malhaire</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Culine</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Aubelle</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Laplanche</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>A risk-adapted study of cisplatin and etoposide, with or without ifosfamide, in patients with metastatic seminoma: results of the GETUG S99 multicenter prospective study.</article-title>
            <source>Eur Urol</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>65</volume>
            <issue>2</issue>
            <fpage>381</fpage>
            <page-range>381-6</page-range>
            <pub-id pub-id-type="pmid">24094847</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28872.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Amin</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Greene</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Edge</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Compton</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Gershenwald</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Brookland</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gress</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Byrd</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Winchester</surname>
                <given-names>DP</given-names>
              </name>
            </person-group>
            <article-title>The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging.</article-title>
            <source>CA Cancer J Clin</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>67</volume>
            <issue>2</issue>
            <fpage>93</fpage>
            <page-range>93-99</page-range>
            <pub-id pub-id-type="pmid">28094848</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28872.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huddart</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Norman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shahidi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Horwich</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Coward</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nicholls</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dearnaley</surname>
                <given-names>DP</given-names>
              </name>
            </person-group>
            <article-title>Cardiovascular disease as a long-term complication of treatment for testicular cancer.</article-title>
            <source>J Clin Oncol</source>
            <year>2003</year>
            <month>Apr</month>
            <day>15</day>
            <volume>21</volume>
            <issue>8</issue>
            <fpage>1513</fpage>
            <page-range>1513-23</page-range>
            <pub-id pub-id-type="pmid">12697875</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
